Market News

Grs Advisors Lowered Equity Comwlth (EQC) Stake by $2.33 Million; Share Value Declined; Clovis Oncology (CLVS) Market Value Declined While Moore Capital Management LP Decreased by $340,000 Its Position

Equity Commonwealth (NYSE:EQC) Logo

Grs Advisors Llc decreased its stake in Equity Comwlth (EQC) by 28.12% based on its latest 2017Q4 regulatory filing with the SEC. Grs Advisors Llc sold 77,704 shares as the company’s stock declined 0.50% with the market. The institutional investor held 198,587 shares of the real estate investment trusts company at the end of 2017Q4, valued at $6.06M, down from 276,291 at the end of the previous reported quarter. Grs Advisors Llc who had been investing in Equity Comwlth for a number of months, seems to be less bullish one the $3.69 billion market cap company. It closed at $30.38 lastly. It is down 3.67% since May 19, 2017 and is downtrending. It has underperformed by 15.22% the S&P500.

Louis Bacon decreased its stake in Clovis Oncology Inc (CLVS) by 16.67% based on its latest 2017Q4 regulatory filing with the SEC. Moore Capital Management Lp sold 5,000 shares as the company’s stock declined 18.56% with the market. The hedge fund run by Louis Bacon held 25,000 shares of the health care company at the end of 2017Q4, valued at $1.70M, down from 30,000 at the end of the previous reported quarter. Moore Capital Management Lp who had been investing in Clovis Oncology Inc for a number of months, seems to be less bullish one the $2.63B market cap company. The stock decreased 3.69% or $1.92 during the last trading session, reaching $50.09. About 1.01M shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 21.43% since May 19, 2017 and is downtrending. It has underperformed by 32.98% the S&P500.

More news for Equity Commonwealth (NYSE:EQC) were recently published by: Businesswire.com, which released: “Equity Commonwealth Reports First Quarter 2018 Results” on May 07, 2018. Twst.com‘s article titled: “Equity Commonwealth: Equity Commonwealth Reports First Quarter 2018 Results” and published on May 07, 2018 is yet another important article.

Among 4 analysts covering Equity Commonwealth (NYSE:EQC), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Equity Commonwealth had 11 analyst reports since August 10, 2015 according to SRatingsIntel. The rating was upgraded by Citigroup to “Neutral” on Friday, September 11. The stock has “Hold” rating by Stifel Nicolaus on Friday, July 14. The rating was upgraded by Bank of America to “Neutral” on Wednesday, September 9. The firm earned “Sell” rating on Monday, August 10 by Zacks. The stock has “Buy” rating by Bank of America on Monday, August 15. The stock of Equity Commonwealth (NYSE:EQC) has “Buy” rating given on Friday, February 16 by Stifel Nicolaus. Citigroup maintained the shares of EQC in report on Thursday, September 1 with “Neutral” rating. The firm has “Hold” rating by Stifel Nicolaus given on Monday, September 18. The stock of Equity Commonwealth (NYSE:EQC) has “Neutral” rating given on Monday, September 14 by Citigroup. As per Tuesday, May 8, the company rating was maintained by JMP Securities.

Analysts await Equity Commonwealth (NYSE:EQC) to report earnings on July, 23. They expect $0.15 EPS, down 40.00% or $0.10 from last year’s $0.25 per share. EQC’s profit will be $18.22M for 50.63 P/E if the $0.15 EPS becomes a reality. After $0.14 actual EPS reported by Equity Commonwealth for the previous quarter, Wall Street now forecasts 7.14% EPS growth.

Investors sentiment decreased to 1.05 in Q4 2017. Its down 0.39, from 1.44 in 2017Q3. It turned negative, as 35 investors sold CLVS shares while 69 reduced holdings. 31 funds opened positions while 78 raised stakes. 49.09 million shares or 3.43% more from 47.46 million shares in 2017Q3 were reported. Stifel Financial Corp holds 0% or 15,948 shares. Wells Fargo Company Mn reported 0.01% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). State Of Wisconsin Invest Board owns 0.01% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 43,082 shares. Art Advsrs Limited Liability holds 0.08% or 25,100 shares. Moreover, Los Angeles Capital Management And Equity Rech has 0.01% invested in Clovis Oncology, Inc. (NASDAQ:CLVS). Susquehanna Int Grp Inc Llp has 366,173 shares. Rmb Capital Mgmt Limited Liability invested in 0.04% or 21,954 shares. Canada Pension Plan Investment Board accumulated 25,700 shares. Columbia Wanger Asset Management Limited Liability reported 0.52% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Aperio Limited Liability Com has invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). Group Incorporated One Trading LP reported 26,196 shares stake. Deutsche Commercial Bank Ag reported 243,628 shares or 0.01% of all its holdings. Swiss Fincl Bank owns 0.01% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 79,050 shares. Putnam Invests Ltd Liability Co holds 0.15% or 984,783 shares. Point72 Asset Mngmt Ltd Partnership stated it has 876,000 shares.

More news for Clovis Oncology, Inc. (NASDAQ:CLVS) were recently published by: Businesswire.com, which released: “Clovis Oncology Announces Presentations at 2018 ASCO Annual Meeting” on May 16, 2018. Seekingalpha.com‘s article titled: “Clovis May 2018 Update” and published on May 16, 2018 is yet another important article.

Since December 15, 2017, it had 0 insider buys, and 7 insider sales for $1.64 million activity. IVERS-READ GILLIAN C sold $162,270 worth of stock or 3,000 shares.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 16 have Buy rating, 0 Sell and 4 Hold. Therefore 80% are positive. Clovis Oncology had 64 analyst reports since September 10, 2015 according to SRatingsIntel. The rating was maintained by Suntrust Robinson on Friday, September 23 with “Buy”. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Hold” rating by WallachBeth Capital on Tuesday, November 17. The firm earned “Neutral” rating on Wednesday, April 13 by JP Morgan. The rating was maintained by Barclays Capital with “Overweight” on Tuesday, February 27. SunTrust maintained Clovis Oncology, Inc. (NASDAQ:CLVS) rating on Friday, April 6. SunTrust has “Buy” rating and $9000 target. The company was upgraded on Tuesday, June 20 by Janney Capital. Piper Jaffray maintained the stock with “Neutral” rating in Monday, November 16 report. The rating was maintained by WallachBeth Capital with “Hold” on Monday, May 9. The rating was initiated by Suntrust Robinson on Friday, August 5 with “Buy”. Credit Suisse maintained it with “Buy” rating and $86.0 target in Thursday, January 18 report.

Clovis Oncology, Inc. (NASDAQ:CLVS) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *